메뉴 건너뛰기




Volumn 62, Issue 3, 2016, Pages 298-304

The impact of enhanced screening and treatment on Hepatitis C in the United States

Author keywords

direct acting antivirals; hepatitis C; people who inject drugs; screening; treatment

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DIRECT ACTING ANTIVIRAL AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

EID: 84962242019     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ894     Document Type: Article
Times cited : (50)

References (39)
  • 1
    • 79961199944 scopus 로고    scopus 로고
    • Hepatitis C virus infection in USA: An estimate of true prevalence
    • Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101
    • (2011) Liver Int , vol.31 , pp. 1090-1101
    • Chak, E.1    Talal, A.H.2    Sherman, K.E.3    Schiff, E.R.4    Saab, S.5
  • 2
    • 73149113990 scopus 로고    scopus 로고
    • Public health impact of antiviral therapy for hepatitis C in the United States
    • Volk ML, Tocco R, Saini S, Lok ASF. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50: 1750-5
    • (2009) Hepatology , vol.50 , pp. 1750-1755
    • Volk, M.L.1    Tocco, R.2    Saini, S.3    Asf, L.4
  • 3
    • 33846457516 scopus 로고    scopus 로고
    • Self-reported hepatitis C virus antibody status and risk behavior in young injectors
    • Hagan H, Campbell J, Thiede H., et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep 2006; 121: 710-9
    • (2006) Public Health Rep , vol.121 , pp. 710-719
    • Hagan, H.1    Campbell, J.2    Thiede, H.3
  • 4
    • 84901911155 scopus 로고    scopus 로고
    • Hepatitis C treatment triumphs
    • Rice CM, Saeed M. Hepatitis C: treatment triumphs. Nature 2014; 510: 43-4
    • (2014) Nature , vol.510 , pp. 43-44
    • Rice, C.M.1    Saeed, M.2
  • 6
    • 43349090325 scopus 로고    scopus 로고
    • Limited uptake of hepatitis C treatment among injection drug users
    • Mehta SH, Genberg BL, Astemborski J., et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33
    • (2008) J Community Health , vol.33 , pp. 126-133
    • Mehta, S.H.1    Genberg, B.L.2    Astemborski, J.3
  • 7
    • 84906678391 scopus 로고    scopus 로고
    • Can hepatitis C be eradicated in the United States?
    • Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States?. Antiviral Res 2014; 110C: 79-93
    • (2014) Antiviral Res , vol.110 C , pp. 79-93
    • Edlin, B.R.1    Winkelstein, E.R.2
  • 8
    • 33646852746 scopus 로고    scopus 로고
    • The prevalence of hepatitis C virus infection in the United States 1999 through 2002
    • Armstrong GL. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705
    • (2006) Ann Intern Med , Issue.144 , pp. 705
    • Armstrong, G.L.1
  • 9
    • 84867288022 scopus 로고    scopus 로고
    • Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965
    • Smith BD, Morgan RL, Beckett GA., et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32
    • (2012) MMWR Recomm Rep , Issue.61 , pp. 1-32
    • Smith, B.D.1    Morgan, R.L.2    Beckett, G.A.3
  • 10
    • 84863393363 scopus 로고    scopus 로고
    • The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. Primary care settings
    • Rein DB, Smith BD, Wittenborn JS., et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-70
    • (2012) Ann Intern Med , vol.156 , pp. 263-270
    • Rein, D.B.1    Smith, B.D.2    Wittenborn, J.S.3
  • 11
    • 84905656313 scopus 로고    scopus 로고
    • The changing burden of hepatitis C virus infection in the United States: Model-based predictions
    • Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014; 161: 170-80
    • (2014) Ann Intern Med , vol.161 , pp. 170-180
    • Kabiri, M.1    Jazwinski, A.B.2    Roberts, M.S.3    Schaefer, A.J.4    Chhatwal, J.5
  • 12
    • 84880998187 scopus 로고    scopus 로고
    • Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy
    • Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57(suppl 2): S39-45
    • (2013) Clin Infect Dis , vol.57 SUPPL2 , pp. S39-S45
    • Martin, N.K.1    Hickman, M.2    Hutchinson, S.J.3    Goldberg, D.J.4    Vickerman, P.5
  • 13
    • 84895766895 scopus 로고    scopus 로고
    • Editorial commentary: Hepatitis C virus testing and drug use in North America is there more than meets the eye?
    • Beckwith CG, Larney S, Flanigan TP. Editorial commentary: hepatitis C virus testing and drug use in North America; is there more than meets the eye?. Clin Infect Dis 2014; 58: 762-4
    • (2014) Clin Infect Dis , vol.58 , pp. 762-764
    • Beckwith, C.G.1    Larney, S.2    Flanigan, T.P.3
  • 14
    • 84901363195 scopus 로고    scopus 로고
    • Estimating the number of persons who inject drugs in the United States by meta-Analysis to calculate national rates of HIV and hepatitis C virus infections
    • Lansky A, Finlayson T, Johnson C., et al. Estimating the number of persons who inject drugs in the United States by meta-Analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One 2014; 9: e97596
    • (2014) PLoS One , vol.9 , pp. e97596
    • Lansky, A.1    Finlayson, T.2    Johnson, C.3
  • 15
    • 84884490240 scopus 로고    scopus 로고
    • Model for hepatitis C virus transmission
    • Elbasha E. Model for hepatitis C virus transmission. Math Biosci Eng 2013; 10: 1045-65
    • (2013) Math Biosci Eng , vol.10 , pp. 1045-1065
    • Elbasha, E.1
  • 16
    • 0026747914 scopus 로고
    • The declining risk of post-Transfusion hepatitis C virus infection
    • Donahue JG, Muñoz A, Ness PM., et al. The declining risk of post-Transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369-73
    • (1992) N Engl J Med , vol.327 , pp. 369-373
    • Donahue, J.G.1    Muñoz, A.2    Ness, P.M.3
  • 17
    • 49649118223 scopus 로고    scopus 로고
    • Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-Analysis and meta-regression
    • Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-Analysis and meta-regression. Hepatology 2008; 48: 418-31
    • (2008) Hepatology , vol.48 , pp. 418-431
    • Thein, H.-H.1    Yi, Q.2    Dore, G.J.3    Krahn, M.D.4
  • 18
    • 84883450412 scopus 로고    scopus 로고
    • Treatment of hepatitis C in the patient with decompensated cirrhosis
    • Everson GT, Bhatt A. Treatment of hepatitis C in the patient with decompensated cirrhosis. Curr Hepat Rep 2013; 12: 236-45
    • (2013) Curr Hepat Rep , vol.12 , pp. 236-245
    • Everson, G.T.1    Bhatt, A.2
  • 19
    • 0033584440 scopus 로고    scopus 로고
    • The prevalence of hepatitis C virus infection in the United States 1988 through 1994
    • Alter MJ, Kruszon-Moran D, Nainan OV., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62
    • N Engl J Med , vol.1999 , Issue.341 , pp. 556-562
    • Alter, M.J.1    Kruszon-Moran, D.2    Nainan, O.V.3
  • 20
    • 46249094710 scopus 로고    scopus 로고
    • Prevalence of hepatitis C virus infection among injection drug users in the United States 1994-2004
    • Amon JJ, Garfein RS, Ahdieh-Grant L., et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 2008; 46: 1852-8
    • (2008) Clin Infect Dis , Issue.46 , pp. 1852-1858
    • Amon, J.J.1    Garfein, R.S.2    Ahdieh-Grant, L.3
  • 21
    • 84962315109 scopus 로고    scopus 로고
    • Factors associated with spontaneous clearance during acute hepatitis C virus infection
    • Grebely J, Dore GJ, Van Der Loeff MS., et al. Factors associated with spontaneous clearance during acute hepatitis C virus infection. J Hepatol 2010; 52: S411
    • (2010) J Hepatol , vol.52 , pp. S411
    • Grebely, J.1    Dore, G.J.2    Van Der Loeff, M.S.3
  • 22
    • 27644489043 scopus 로고    scopus 로고
    • Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: A European case-control study
    • Yazdanpanah Y, De Carli G, Migueres B., et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005; 41: 1423-30
    • (2005) Clin Infect Dis , vol.41 , pp. 1423-1430
    • Yazdanpanah, Y.1    De Carli, G.2    Migueres, B.3
  • 23
    • 0031836665 scopus 로고    scopus 로고
    • Serum and liver HCV RNA levels in patients with chronic hepatitis C: Correlation with clinical and histological features
    • De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998; 42: 856-60
    • (1998) Gut , vol.42 , pp. 856-860
    • De Moliner, L.1    Pontisso, P.2    De Salvo, G.L.3    Cavalletto, L.4    Chemello, L.5    Alberti, A.6
  • 24
    • 0034918152 scopus 로고    scopus 로고
    • Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers
    • Yeo AET, Ghany M, Conry-Cantilena C., et al. Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. J Viral Hepat 2001; 8: 256-63
    • (2001) J Viral Hepat , vol.8 , pp. 256-263
    • Aet, Y.1    Ghany, M.2    Conry-Cantilena, C.3
  • 25
    • 20444375028 scopus 로고    scopus 로고
    • Dynamics of viremia in early hepatitis C virus infection
    • Glynn SA, Wright DJ, Kleinman SH., et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45: 994-1002
    • (2005) Transfusion , vol.45 , pp. 994-1002
    • Glynn, S.A.1    Wright, D.J.2    Kleinman, S.H.3
  • 26
    • 0036789296 scopus 로고    scopus 로고
    • Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore Maryland
    • Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Clin Infect Dis 2002; 35: 783-8
    • (2002) Clin Infect Dis , vol.35 , pp. 783-788
    • Ompad, D.C.1    Fuller, C.M.2    Vlahov, D.3    Thomas, D.4    Strathdee, S.A.5
  • 27
    • 84937029422 scopus 로고    scopus 로고
    • A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs
    • Spelman T, Morris MD, Zang G., et al. A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. J Epidemiol Community Heal 2015; 69: 745-52
    • (2015) J Epidemiol Community Heal , vol.69 , pp. 745-752
    • Spelman, T.1    Morris, M.D.2    Zang, G.3
  • 28
    • 84860297348 scopus 로고    scopus 로고
    • Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: Towards a vaccine
    • Grebely J, Prins M, Hellard M., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012; 12: 408-14
    • (2012) Lancet Infect Dis , vol.12 , pp. 408-414
    • Grebely, J.1    Prins, M.2    Hellard, M.3
  • 29
    • 72249087933 scopus 로고    scopus 로고
    • Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection
    • Osburn WO, Fisher BE, Dowd KA., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-24
    • (2010) Gastroenterology , vol.138 , pp. 315-324
    • Osburn, W.O.1    Fisher, B.E.2    Dowd, K.A.3
  • 30
    • 33746546870 scopus 로고    scopus 로고
    • Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States
    • Nainan OV, Alter MJ, Kruszon-Moran D., et al. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84
    • (2006) Gastroenterology , vol.131 , pp. 478-484
    • Nainan, O.V.1    Alter, M.J.2    Kruszon-Moran, D.3
  • 31
    • 84877739274 scopus 로고    scopus 로고
    • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
    • Jacobson IM, Gordon SC, Kowdley KV., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77
    • (2013) N Engl J Med , vol.368 , pp. 1867-1877
    • Jacobson, I.M.1    Gordon, S.C.2    Kowdley, K.V.3
  • 32
    • 84892619580 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
    • Sulkowski MS, Gardiner DF, Rodriguez-Torres M., et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21
    • (2014) N Engl J Med , vol.370 , pp. 211-221
    • Sulkowski, M.S.1    Gardiner, D.F.2    Rodriguez-Torres, M.3
  • 33
    • 84939262043 scopus 로고    scopus 로고
    • Lack of health insurance limits the benefits of hepatitis C virus screening: Insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study
    • Ditah I, Al Bawardy B, Gonzalez HC., et al. Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C Follow-Up Study. Am J Gastroenterol 2015; 110: 1126-33
    • (2015) Am J Gastroenterol , vol.110 , pp. 1126-1133
    • Ditah, I.1    Al Bawardy, B.2    Gonzalez, H.C.3
  • 34
    • 84923486405 scopus 로고    scopus 로고
    • Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department
    • Galbraith JW, Franco RA, Donnelly JP., et al. Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. Hepatology 2015; 61: 776-82
    • (2015) Hepatology , vol.61 , pp. 776-782
    • Galbraith, J.W.1    Franco, R.A.2    Donnelly, J.P.3
  • 35
    • 84892397492 scopus 로고    scopus 로고
    • Barriers and facilitators of hepatitis C screening among people who inject drugs: A multicity, mixed-methods study
    • Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multicity, mixed-methods study. Harm Reduct J 2014; 11: 1
    • (2014) Harm Reduct J , vol.11 , pp. 1
    • Barocas, J.A.1    Brennan, M.B.2    Hull, S.J.3    Stokes, S.4    Fangman, J.J.5    Westergaard, R.P.6
  • 36
    • 84912062011 scopus 로고    scopus 로고
    • Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3
    • Abenavoli L, Masarone M, Peta V., et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol 2014; 20: 15233-40
    • (2014) World J Gastroenterol , vol.20 , pp. 15233-15240
    • Abenavoli, L.1    Masarone, M.2    Peta, V.3
  • 37
    • 63449089688 scopus 로고    scopus 로고
    • Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users
    • Hahn JA, Wylie D, Dill J., et al. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. Epidemics 2009; 1: 47-57
    • (2009) Epidemics , vol.1 , pp. 47-57
    • Hahn, J.A.1    Wylie, D.2    Dill, J.3
  • 38
    • 84924901173 scopus 로고    scopus 로고
    • Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States
    • Chhatwal J, Kanwal F, Roberts MS, Dunn M.A. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015; 162: 397-406
    • (2015) Ann Intern Med , vol.162 , pp. 397-406
    • Chhatwal, J.1    Kanwal, F.2    Roberts, M.S.3    Dunn, M.A.4
  • 39
    • 70449085441 scopus 로고    scopus 로고
    • Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion
    • Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49: 2454-89
    • (2009) Transfusion , vol.49 , pp. 2454-2489
    • Kleinman, S.H.1    Lelie, N.2    Busch, M.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.